Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
- None.
- None.
Company Announces Participation in BTIG Virtual Biotechnology Conference
In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming investor conferences:
- BTIG Virtual Biotechnology Conference 2023 – Fireside chat presentation will be held virtually on Monday, August 7th, 2023 at 3:00 PM ET.
A replay of the fireside chat from the BTIG conference can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations following the event.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The Company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). Agenus is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726366654/en/
Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com
Media Contact
781-674-4784
communications@agenusbio.com
Source: Agenus
FAQ
When will Agenus release its Q2 2023 financial results?
Who is the CEO of Agenus?
What conference will Dr. Garo Armen participate in?
When is the BTIG Virtual Biotechnology Conference?
What time will Dr. Garo Armen's fireside chat presentation be held?